Precision BioSciences Inc expected to post a loss of $1.57 a share - Earnings Preview
Precision BioSciences Inc
DTIL is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025The Durham North Carolina-based company is expected to report a 87.4% decrease in revenue to $6.267 million from $49.9 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Precision BioSciences Inc is for a loss of $1.57 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Precision BioSciences Inc is $21.50, about 77.5% above its last closing price of $4.84
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.86 | -1.72 | -2.21 | Missed | -28.7 |
Dec. 31 2025 | -1.96 | -2.22 | Missed | -13.1 | |
Sep. 30 2024 | -2.23 | -1.92 | -2.25 | Missed | -17 |
Jun. 30 2024 | -1.68 | -1.50 | 4.67 | Beat | 410.3 |
Mar. 31 2024 | -2.01 | -1.91 | -0.35 | Beat | 81.7 |
Dec. 31 2023 | -3.99 | -2.05 | -4.06 | Missed | -98.3 |
Sep. 30 2023 | -5.03 | -4.87 | -2.10 | Beat | 56.9 |
Jun. 30 2023 | -7.52 | -7.32 | -3.00 | Beat | 59 |
This summary was machine generated August 5 at 14:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
